论文部分内容阅读
[目的]探讨新辅助化疗对局部进展期胃癌患者的手术切除率、耐受性及并发症、生存期的影响。[方法]回顾性分析2004年1月1日至2010年12月31日收治并行新辅助化疗的局部进展期胃癌患者75例,与同期收治的68例局部进展期胃癌直接手术患者进行对照研究,比较两组患者的手术切除率和生存期。[结果]新辅助化疗组患者手术切除率及根治率均高于对照组(P<0.05),3年、5年生存率亦高于对照组(P<0.05)。两组患者并发症差异无统计学意义。[结论]对于局部进展期胃癌患者术前行新辅助化疗,可以提高切除率,减少手术的盲目性,并不增加手术难度及并发症,且能延长生存时间。
[Objective] To investigate the effect of neoadjuvant chemotherapy on the surgical resection rate, tolerance, complications and survival in patients with locally advanced gastric cancer. [Methods] A retrospective analysis of 75 patients with locally advanced gastric cancer treated with concurrent neoadjuvant chemotherapy from January 1, 2004 to December 31, 2010 was performed and compared with 68 patients with locally advanced gastric cancer who underwent concurrent surgery. Surgical resection rates and survival were compared between the two groups. [Results] The rates of resection and cure in patients receiving neoadjuvant chemotherapy were significantly higher than those in control group (P <0.05). The 3-year and 5-year survival rates were also higher than those in control group (P <0.05). There was no significant difference in the complication between the two groups. [Conclusion] The neoadjuvant chemotherapy preoperatively in patients with locally advanced gastric cancer can improve the resection rate and reduce the blindness of operation without increasing the difficulty and complications of operation and prolonging the survival time.